- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04453241
Immunogenicity and Safety Study of NBP615 in Healthy Female
September 24, 2021 updated by: SK Bioscience Co., Ltd.
A Randomized, Double-Blinded, Active Controlled, Phase I/ II Clinical Trial to Assess the Immunogenicity, Safety, and Tolerability of NBP615 Vaccine in Healthy Female Participants Aged 19 to 26 Years and Adolescent Aged 9 to 13 Years
This was a randomized, double-blind, active-controlled, phase I/II clinical trial to enroll 200 healthy female including 80 healthy adult aged 19 to 26 years and 120 adolescents aged 9 to 13 years.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
In order to confirm the safety, 80 healthy adult were enrolled first.
Eligible subjects were randomized into 1:1 ratio to receive three doses of either test vaccine (NPB615) or comparator vaccine (Gardasil).
The safety of the test vaccine (NBP615) was confirmed by 2nd vaccination in adult subjects.
After that, enrolment of 120 adolescent subjects proceeded.
Eligible subjects who previously agreed to participate in the study were screened and only those subjects who met the inclusion/exclusion criteria were randomized in to 1:1 to receive two doses of test vaccine (NBP615) or comparator (Gardasil pre-filled syringe).
0.5 ml Intramuscular injection at were given at each vaccination and two blood sample, pre vaccine and post vaccine 4 weeks after completion of vaccine were collected to assess the immunogenicity of NBP615 and Gardasil, comparator vaccine.
Solicited adverse events occurred up to 7 days after each dose of the investigational product were collected in the diary card.
Unsolicited adverse events occurred up to 28 days after each dose of the investigational product were collated in the diary card.
Serious adverse events were collected during the entire study period.
In addition to this safety data was collected through the study period by active contact with the study participants by doing home visit or by telephone contact.
Study Type
Interventional
Enrollment (Actual)
200
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Seongnam-si
-
Gyeonggi-do, Seongnam-si, Korea, Republic of, 13494
- SK Bioscience
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
9 years to 26 years (Child, Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
[Inclusion Criteria]
- Healthy adult(19 to 26 years)/adolescent(9 to 13 years) of age at the time of the 1st vaccination
- Participant fully understands study procedures, and voluntarily agrees to participate in the study and follow the study procedure by giving written informed consent
[Exclusion Criteria]
- Received a marketed Human papillomavirus(HPV) vaccine, or had participated in an HPV vaccine clinical trial and had received either active agent or placebo.
- History of hypersensitivity to any component of the study vaccines.
- Currently immunocompromised or was diagnosed as having a congenital or acquired immunodeficiency, Human Immunodeficiency Virus(HIV) infection, lymphoma, leukemia, systemic lupus erythematosus (SLE), rheumatoid arthritis, juvenile rheumatoid arthritis (JRA), inflammatory bowel disease, other autoimmune condition, or other immune disorder which is decided to be medically significant by the investigator.
- Received immunoglobulins and/or blood product within 3 months preceding the first dose of study vaccine or planned administration during the study period.
- Receiving or had received chemotherapy, immunosuppressive therapies, or radiation therapy in the year prior to enrolment.
- Chronic administration (>14 days) of immune-suppressants or immune modulating drugs within 3 months prior to the first vaccine dose or planned administration during the study period. Inhaled, nasal and topical steroids are allowed.
- Participant with severe thrombocytopenia or any coagulation disorder that would contraindicate intramuscular injections.
- Subject has active cervical disease or a significant history of cervical disease.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: NBP615
Adult : 3 doses of vaccination Adolescent :2 doses of vaccination
|
Intramuscular injection, 0.5ml
|
Active Comparator: GARDASIL
Adult : 3 doses of vaccination Adolescent :2 doses of vaccination
|
Intramuscular injection, 0.5ml
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Geometric mean titer measured by Enzyme-linked Immunosorbent Assay(ELISA)
Time Frame: 4 weeks after the vaccination
|
geometric mean titer against anti-HPV 6, 11, 16, and 18 for each treatment group
|
4 weeks after the vaccination
|
seroconversion rate measured by Enzyme-linked Immunosorbent Assay(ELISA)
Time Frame: 4 weeks after the vaccination
|
proportion of subjects who seroconverted from seronegative at baseline to seropositive at post vaccination for anti-HPV 6, 11, 16, and 18
|
4 weeks after the vaccination
|
Geometric mean titer measured by pseudovirion-based neutralization assay(PBNA)
Time Frame: 4 weeks after the vaccination
|
geometric mean titer against anti-HPV 6, 11, 16, and 18 for each treatment
|
4 weeks after the vaccination
|
Incidence rate of Solicited Adverse Event
Time Frame: 7 days after the vaccination
|
Solicited local/systemic adverse event after vaccination
|
7 days after the vaccination
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: K Zaman, MD, International Centre for Diarrhoeal Disease Research, Bangladesh
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 22, 2018
Primary Completion (Actual)
December 30, 2019
Study Completion (Actual)
December 30, 2019
Study Registration Dates
First Submitted
June 26, 2020
First Submitted That Met QC Criteria
June 26, 2020
First Posted (Actual)
July 1, 2020
Study Record Updates
Last Update Posted (Actual)
October 1, 2021
Last Update Submitted That Met QC Criteria
September 24, 2021
Last Verified
June 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PR-18062
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cervical Cancer
-
University of California, San DiegoWithdrawnCervical Cancer | Cervical Cancer Stage | Cervical Cancer Stage IB2 | Cervical Cancer Stage IB1 | Cervical Cancer Stage I | Cervical Cancer Stage IB | Cervical Cancer Stage II | Cervical Cancer Stage IIa | Cervical Cancer, Stage IIB | Cervical Cancer, Stage III | Cervical Cancer Stage IIIB | Cervical Cancer... and other conditionsUnited States
-
M.D. Anderson Cancer CenterWithdrawnStage IB3 Cervical Cancer FIGO 2018 | Stage II Cervical Cancer FIGO 2018 | Stage IIA Cervical Cancer FIGO 2018 | Stage IIA1 Cervical Cancer FIGO 2018 | Stage IIA2 Cervical Cancer FIGO 2018 | Stage IIB Cervical Cancer FIGO 2018 | Stage III Cervical Cancer FIGO 2018 | Stage IIIA Cervical Cancer FIGO... and other conditions
-
Abramson Cancer Center of the University of PennsylvaniaWithdrawnCervical Cancer | Stage IB Cervical Cancer | Stage IIA Cervical Cancer | Stage IIB Cervical Cancer | Stage III Cervical Cancer | Stage IVA Cervical Cancer
-
National Cancer Institute (NCI)CompletedCervical Adenocarcinoma | Cervical Squamous Cell Carcinoma | Stage IB Cervical Cancer | Stage IIA Cervical Cancer | Stage IIB Cervical Cancer | Stage III Cervical Cancer | Stage IVA Cervical Cancer | Stage IVB Cervical CancerUnited States
-
Mayo ClinicNational Cancer Institute (NCI)RecruitingCervical Adenosquamous Carcinoma | Cervical Squamous Cell Carcinoma, Not Otherwise Specified | Recurrent Cervical Carcinoma | Stage IB3 Cervical Cancer FIGO 2018 | Stage II Cervical Cancer FIGO 2018 | Stage IIA Cervical Cancer FIGO 2018 | Stage IIA1 Cervical Cancer FIGO 2018 | Stage IIA2 Cervical... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingStage IA Cervical Cancer | Stage IB Cervical Cancer | Stage IA1 Cervical Cancer | Stage IA2 Cervical Cancer | Stage IB1 Cervical Cancer | Stage IB2 Cervical Cancer | Stage IB3 Cervical CancerUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)CompletedCervical Adenocarcinoma | Cervical Squamous Cell Carcinoma | Stage IB Cervical Cancer | Stage IIA Cervical Cancer | Stage IIB Cervical Cancer | Stage III Cervical Cancer | Stage IVA Cervical CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)CompletedRecurrent Cervical Cancer | Stage IVA Cervical Cancer | Stage IVB Cervical Cancer | Stage IIIA Cervical Cancer | Stage IIIB Cervical CancerUnited States
-
Shanghai First Maternity and Infant HospitalNot yet recruitingCervical Cancer, Stage IIB | Cervical Cancer Stage IIIB | Cervical Cancer Stage IIIA | Cervical Cancer, Stage IVA
-
Institut de Cancérologie de LorraineCompletedCervical Adenocarcinoma | Stage IB Cervical Cancer | Stage III Cervical Cancer | Stage II Cervical CancerFrance